Bernardo, S, Brunet, L, Thomas, QD, Bracquemond, D, Bouclier, C, Colomb, M, Mancini, M, Fabbrizio, E, Santos, A, Rasamizafy, SF, Maacha, AM, Giry, A, Bousquet-Mur, E, Papon, L, Goussard, M, Fremin, C, Pasquier, A, Rodríguez, M, Travert, C, Pujol, JL, Linares, LK, Heron-Milhavet, L, Djiane, A, Ferrer, I, Paz-Ares, L, Quantin, X, Montuenga, LM, Tourriere, H, Maraver, A (2026).
NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum
Ballesteros-González, I, Hernández-Navas, I, Brehey, O, Lechuga, CG, Salmon, M, Scotece, M, Velasco-Vicente, R, Flores-Gomez, AA, Cebriá, A, Simon-Carrasco, L, Jiménez, G, Musteanu, M, Guerra, C, Domínguez, O, Caleiras, E, Blanco-Aparicio, C, Pons, T, Ferrer, I, Paz-Ares, L, Torres-Ruiz, R, Rodríguez-Perales, S, Barbacid, M, Drosten, M (2025).
The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations
Otero-Rosales, M, Alvarez-González, M, Pazos, I, de Luxán-Delgado, B, Del Marro, S, Pozo-Agundo, E, Rodríguez-Santamaría, M, López-Fernández, A, Corte-Torres, D, Granda-Díaz, R, Alvarez-Teijeiro, S, Fernández-Vega, I, Lorz, C, García-Escudero, R, Rodrigo, JP, Tzelepis, K, Vassiliou, G, Ferrer, I, Alvarez-Fernández, M, García-Pedrero, JM, Hermida-Prado, F (2025).
CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer
Redin, E, Otegui, N, Santos, M, Leon, S, Redrado, M, Serrano, D, de Pierola, EF, Russo-Cabrera, JS, Ferrer, I, Olmedo, M, Diaz-Lagares, A, Houry, M, Vicent, S, Vilalta, A, Mondelo-Macía, P, García-González, J, León-Mateos, L, Gonzalez, A, Paz-Ares, L, López, R, Sanmamed, MF, Montuenga, L, Calvo, A (2025).
Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
Jiménez-Reinoso, A, Molero-Abraham, M, Cirauqui, C, Blanco, B, Garrido-Martin, EM, Nehme-Alvarez, D, Domínguez-Alonso, C, Ramírez-Fernández, A, Díez-Alonso, L, Nuñez-Buiza, A, González-Murillo, A, Tobes, R, Pareja, E, Ramírez-Orellana, M, Rodriguez-Peralto, JL, Ferrer, I, Zugazagoitia, J, Paz-Ares, L, Alvarez-Vallina, L (2024).
CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts
Molina-Pinelo S, Ferrer Sánchez I, Najarro P, Paz-Ares L, Fernández L, Castelló N, Richart López LA, Rodríguez Gambarte JD, Sanz García M, Salinas A, Suárez R, Romero-Romero B, Martín-Juan J, Viñuela ME, Butler RG, de Pedro N (2024).
Telomere-based risk models for the early diagnosis of lung cancer.
Figarol, S, Delahaye, C, Gence, R, Doussine, A, Cerapio, JP, Brachais, M, Tardy, C, Béry, N, Asslan, R, Colinge, J, Villemin, JP, Maraver, A, Ferrer, I, Paz-Ares, L, Kessler, L, Burrows, F, Lajoie-Mazenc, I, Dongay, V, Morin, C, Florent, A, Pagano, S, Taranchon-Clermont, E, Casanova, A, Pradines, A, Mazieres, J, Favre, G, Calvayrac, O (2024).
Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies
Macaya, I, Roman, M, Welch, C, Entrialgo-Cadierno, R, Salmon, M, Santos, A, Feliu, I, Kovalski, J, Lopez, I, Rodriguez-Remirez, M, Palomino-Echeverria, S, Lonfgren, SM, Ferrero, M, Calabuig, S, Ludwig, IA, Lara-Astiaso, D, Jantus-Lewintre, E, Guruceaga, E, Narayanan, S, Ponz-Sarvise, M, Pineda-Lucena, A, Lecanda, F, Ruggero, D, Khatri, P, Santamaria, E, Fernandez-Irigoyen, J, Ferrer, I, Paz-Ares, L, Drosten, M, Barbacid, M, Gil-Bazo, I, Vicent, S (2023).
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer